Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Neoadjuvant chemoradiotherapy for locally advanced rectal cancer has been shown to decrease rates of local recurrence and more than double the rate of sphincter-preserving surgery. There is now compelling evidence that pathological complete response is an independent predictor of likelihood of local recurrence, distal metastases, disease-free and overall survival in locally advanced rectal cancer following neoadjuvant chemoradiotherapy. Pathological regression grading can therefore guide clinical decisions about salvage surgical strategies, adjuvant therapy and long-term surveillance. No universally recognised regression grading system currently exists for pathologists presented with resected tumour specimens following neoadjuvant chemoradiotherapy. The purpose of this review is to highlight the relevance of accurate tumour regression grading in achieving optimal clinical care for patients with rectal cancer.

Original publication

DOI

10.1136/jclinpath-2012-200958

Type

Journal article

Journal

J Clin Pathol

Publication Date

10/2012

Volume

65

Pages

867 - 871

Keywords

Chemoradiotherapy, Consensus, Humans, Long-Term Care, Neoadjuvant Therapy, Neoplasm Grading, Neoplasm Metastasis, Neoplasm Recurrence, Local, Rectal Neoplasms, Remission Induction